News 

U.S. court denies Jazz Pharma bid to revive narcolepsy drug patents

“Amneal has sought to invalidate other Jazz patents covering Xyrem through litigation in federal court in New Jersey” writes Midwest Communications Inc for 95kqds.com. Jazz said in a statement it was disappointed in the ruling but that it only involves a “subset” of its patents covering Xyrem.The U.S. Court of Appeals for the Federal Circuit affirmed a series of rulings in favor of Amneal that the Jazz patents described obvious ideas.”We remain confident in the strength of our remaining patent estate for Xyrem,” Jazz said.(Reuters) – A U.S. appeals court…

Read More
News Stocks 

Harry Boxer’s four health-care stocks to watch

“ABUS, +9.67% jumped 25 cents, or 2.8%, to $9.05 on Tuesday on 597,300 shares traded, nearly double its average volume” writes Harry Boxer for marketwatch.com. A break over the June 8 high of $8.25 could get the stock to next lateral resistance just under $10.Health-care stocks continue to dominate our list of top charts to watch.NEPT, +4.24% edged up 18 cents to $3.23 on just under 800,000 shares traded Tuesday on no news.MRNS, -2.13% popped 63 cents, or 8.5%, to $8.04 on over 1 million shares traded Tuesday. Source: marketwatch.com Share…

Read More
News 

Europe recalls generic heart drug made in China on cancer fears

“The European Medicines Agency said the recall followed identification of the impurity in the active substance valsartan manufactured by Zhejiang Huahai Pharmaceuticals, a company in Linhai, China” writes Midwest Communications Inc for 95kqds.com. Valsartan was originally developed by Novartis and the Swiss company marketed it as Diovan, but it is now off patent and is used in a number of generic medicines. Source: 95kqds.com Share This:

Read More
News 

Verrica Pharmaceuticals to offer 5 million shares in IPO priced at $14 to $16 each

“Verrica Pharmaceuticals VRCA, +0.00% set the terms for its initial public offering on Tuesday, saying it will offer 5 million shares priced at $14 to $16 each” writes Ciara Linnane for marketwatch.com. The company would raise $75 million at the midpoint of the range.The company is planning to list on Nasdaq, under the ticker symbol “VRCA.” BofA Merrill Lynch, Jefferies and Cowen are underwriters on the deal.The company is a clinical-stage drug company that specializes in dermatological products for the treatment of skin diseases with significant unmet needs. Proceeds of…

Read More
News 

Ionic Pharmaceuticals shares jump 3% premarket on news of license deal with AstraZeneca

“Ionis Pharmaceuticals Inc. shares IONS, -4.37% rose 3% premarket Monday, after the company unveiled a licensing deal with AstraZeneca PlC AZN, +0.20% for a treatment for nonalcoholic steatohepatitis (NASH), or fatty liver” writes Ciara Linnane for marketwatch.com. The company will be entitled to up to $300 million in additional development and regulatory milestone payments, as well tiered royalties up to the low teens from sales of the drug. Source: marketwatch.com Share This:

Read More
News 

Sonoma Pharmaceuticals shares jump 30% premarket after FDA approves skin gel

“Sonoma Pharmaceuticals Inc. shares SNOA, +17.08% surged 30% in premarket trade Thursday, after the company said the U.S. Food and Drug Administration has approved its antimicrobial post-therapy gel” writes Ciara Linnane for marketwatch.com. In 2013, dermatology surgeons performed more than 9.5 million treatments, up almost 22% from the previous year, said Sonoma, citing the Clinical, Cosmetic and Investigational Dermatology Journal. Source: marketwatch.com Share This:

Read More
News 

Martin Shkreli sentenced to seven years in jail for securities fraud

“Pharma felon Martin Shkreli got a dose of reality Friday when a Brooklyn judge slapped him with seven years behind bars for securities fraud” writes Emily Saul for marketwatch.com. Brooklyn federal court judge Kiyo Matsumoto handed down the sentence to the ever-arrogant 34-year-old after he broke down into tears as he made one last plea for leniency. “I was never motivated by money. Source: marketwatch.com Share This:

Read More
News 

Prosecutors want a judge to sentence Martin Shkreli to at least 15 years in prison

“Prosecutors have asked a federal judge in Brooklyn to sentence former pharmaceutical executive Martin Shkreli to at least 15 years in prison, CNBC reports” writes Lydia Ramsey for businessinsider.com. I should have known better,” Shkreli wrote in a letter to the judge.On Monday, the judge ordered Shkreli to forfeit $7.36 million in assets, which could include Shkreli’s $5 million E-Trade account, stake in the pharmaceutical company Vyera Pharmaceuticals (formerly Turing Pharmaceuticals), the Wu-Tang Clan album Shkreli purchased in 2015, a Lil Wayne album, an enigma machine, and a Picasso painting. Source: businessinsider.com Share…

Read More
News 

Valeant’s revenue slides as competition heats up

“(Reuters) – Valeant Pharmaceuticals’ forecast for 2018 revenue fell below Wall Street estimates, as the company faces intensifying competition for some of its major products” writes Manas Mishra for businessinsider.com. The company on Wednesday forecast 2018 revenue of $8.10 billion to $8.30 billion. Revenue fell 10 percent to $2.16 billion, just shy of analysts’ expectations of $2.17 billion. Source: businessinsider.com Share This:

Read More
News 

Valeant reports profit in fourth quarter on $1.3 billion tax benefit

“FILE PHOTO: File photo of the headquarters of Valeant Pharmaceuticals International Inc in Laval Thomson Reuters (Reuters) – Valeant Pharmaceuticals on Wednesday reported a profit in the fourth quarter compared to a year-earlier loss, as it booked a one-time benefit because of new U.S. tax laws” reports businessinsider.com. The Canada-based drugmaker reported a net income of $513 million or $1.45 per share in the quarter ended Dec. 31, compared to a loss of $515 million or $1.47 per share a year earlier. It recorded a one-time benefit from income taxes…

Read More